Astellas and BMT CTN Report P-III Trial (MORPHO) Results of Gilteritinib for the Treatment of Acute Myeloid Leukemia
Shots:
- The P-III trial (MORPHO) evaluating gilteritinib (120mg) as a maintenance therapy vs PBO following allogeneic HSCT in 356 patients with a diagnosis of AML harboring an FLT3/ITD mutation across North America, EU & Asia-Pacific region, incl. Japan. The study was conducted in collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
- The study failed to meet its pre-defined 1EPs of RFS. The results will be submitted for publication and at upcoming medical meetings
- Gilteritinib is an FMS-like tyrosine kinase 3 inhibitor & showed activity against FLT3-ITD. The therapy was available as Xospata in the US, Japan, China & selected EU countries for adult patients who have r/r FLT3+ AML
Ref: Astellas | Image: Astellas
Related News :- Astellas' Xospata (gilteritinib) Receives NMPA's Conditional Approval for R/R AML with a FLT3 Mutation
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
